Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia
Leukocyte immunoglobulin (Ig)-like receptor Bs (LILRBs), a family of type I transmembrane glycoproteins, are known to inhibit immune activation. Here, we comprehensively evaluated the molecular, prognostic, and immunological characteristics of LILRB members in a broad spectrum of cancer types, focus...
Hlavní autoři: | , , , , , , , , , , |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
Elsevier
2022-09-01
|
Edice: | Molecular Therapy: Oncolytics |
Témata: | |
On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2372770522000778 |